FDA: Eisai drug increases acidosis risk

The FDA warned doctors that Eisai's epilepsy drug Zonegran can cause a metabolic disorder--acidosis--that can increase the risk of kidney stones and bone disease; the drug's label will be updated accordingly, the agency said. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.